Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

NCT00107913 is registered in ClinicalTrials.gov with Hematology and Oncology Specialists as lead sponsor.

NCT NCT00107913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00107913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura
Lead sponsor
Hematology and Oncology Specialists
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2001
Completion date
April 30, 2005
Enrollment
10
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune thrombocytopenic purpura